Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients
| Authors | |
|---|---|
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | Anticancer Research |
| MU Faculty or unit | |
| Citation | KISS, Igor, Jitka MLČOCHOVÁ, Zbyněk BORTLÍČEK, Alexandr POPRACH, Jiří DRÁBEK, Petra VYCHYTILOVÁ, Marek SVOBODA, Tomáš BÜCHLER, Stanislav BATKO, Aleš RYŠKA, Marian HAJDÚCH and Ondřej SLABÝ. Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients. Anticancer Research. Athens: INT INST ANTICANCER RESEARCH, 2016, vol. 36, No 9, p. 4955-4959. ISSN 0250-7005. Available from: https://dx.doi.org/10.21873/anticanres.11063. |
| web | http://ar.iiarjournals.org/content/36/9/4955.abstract |
| Doi | http://dx.doi.org/10.21873/anticanres.11063 |
| Field | Oncology and hematology |
| Keywords | KRAS; Metastatic colorectal cancer; cetuximab; miR-31-5p; microRNA; panitumumab |
| Description | Background: In metastatic colorectal cancer (mCRC), panitumumab is generally considered to be ineffective after the progression on cetuximab therapy. However, few studies have demonstrated that a small subset of mCRC patients may benefit from panitumumab in this setting. Patients and Methods: In our study, wild-type KRAS mCRC patients, enrolled into the nationwide Czech registry CORECT between January 2007 and December 2012, were screened for panitumumab therapy after progression on cetuximab. Results: We identified 26 mCRC in the registry with well documented progression on cetuximab in combination with irinotecan-based chemotherapy (FOLFIRI or irinotecan alone) who received panitumumab monotherapy. Partial response (PR) was achieved in 3 (11.5%) patients and stable disease (SD) in 7 (26.9%) patients after 8 weeks of therapy. Thirteen (50.0%) patients had evidence of progressive disease (PD) and in 3 (11.5%) cases response was not available. Furthermore, we confirmed that higher expression levels of newly described biomarker, miR-31-5p, in tumor are significantly associated with shorter progression-free survival (PFS) in patients treated with cetuximab (p=0.038); however, we did not observe association between miR-31-5p and response to panitumumab in mCRC patients after progression on cetuximab. Conclusion: It remains possible that a subset of mCRC patients may benefit from panitumumab after progression on cetuximab. |
| Related projects: |
|